VBLT - VBL Therapeutics gets green light for VB-111 study in ovarian cancer shares up 16%

VBL Therapeutics (VBLT) gains 16% premarket after the independent Data Safety Monitoring Committee ((DSMC)) announces review of OVAL Phase 3 study of VB-111 in recurrent ovarian cancer.The committee found no safety issues with the trial and recommended its continuation as planned. Next DSMC review is expected during Q3, followed by completion of enrollment at year end or in early 2022. In March 2020, the Company announced results of the first interim analysis in the OVAL study, which reviewed and assessed CA-125 response. The overall response rate across both arms was 53%.In December 2020, the company expanded the ovarian cancer trial in Europe.Previously (Aug. 12, 2020): VBL Therapeutics late-stage study of lead drug in ovarian cancer to continue

For further details see:

VBL Therapeutics gets green light for VB-111 study in ovarian cancer, shares up 16%